154 related articles for article (PubMed ID: 34049980)
1. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract][Full Text] [Related]
2. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [
Johnsson K; Brynolfsson J; Sahlstedt H; Nickols NG; Rettig M; Probst S; Morris MJ; Bjartell A; Eiber M; Anand A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1041-1051. PubMed ID: 34463809
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.
García-Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2467-2483. PubMed ID: 38520513
[TBL] [Abstract][Full Text] [Related]
6. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
7. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
Liu Y; Zhang X; Liu J; Zhang J; Xu B
Nucl Med Commun; 2022 Jun; 43(6):725-730. PubMed ID: 35560134
[TBL] [Abstract][Full Text] [Related]
8. Prospective Evaluation of
Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
[No Abstract] [Full Text] [Related]
9. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study.
Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG
J Nucl Med; 2022 Oct; 63(10):1531-1536. PubMed ID: 36008118
[TBL] [Abstract][Full Text] [Related]
10. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU
Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
[TBL] [Abstract][Full Text] [Related]
11. Prostate Specific Membrane Antigen Targeted
Gorin MA; Rowe SP; Patel HD; Vidal I; Mana-Ay M; Javadi MS; Solnes LB; Ross AE; Schaeffer EM; Bivalacqua TJ; Partin AW; Pienta KJ; Szabo Z; De Marzo AM; Pomper MG; Allaf ME
J Urol; 2018 Jan; 199(1):126-132. PubMed ID: 28736318
[TBL] [Abstract][Full Text] [Related]
12.
Ortega C; Schaefferkoetter J; Veit-Haibach P; Anconina R; Berlin A; Perlis N; Metser U
J Nucl Med; 2020 Nov; 61(11):1615-1620. PubMed ID: 32198311
[TBL] [Abstract][Full Text] [Related]
13. Can
Liu Y; Niu S; Luan X; Zhang X; Liu J; Zhang J; Wang R; Xu B; Zhang X
Transl Androl Urol; 2023 Jan; 12(1):83-89. PubMed ID: 36760865
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
16.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
17. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using
Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484
[TBL] [Abstract][Full Text] [Related]
18. Matched-Pair Comparison of
Wondergem M; van der Zant FM; Broos WAM; Knol RJJ
J Nucl Med; 2021 Oct; 62(10):1422-1429. PubMed ID: 33547211
[TBL] [Abstract][Full Text] [Related]
19. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
20. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]